Evidence map›Paper›PMID 40765418›Full record

ArticlePhytotherapy research : PTR2025

Salvianolic Acid A Mitigates Osteoporotic Bone Loss by Repressing Reactive Oxygen Species via the Nrf2-HO-1 Pathway.

Hao Qiu, Chenhui Cai, Ying Zhang, Sizhen Yang, Xu Hu, Tongwei Chu

Abstract read
In one paragraph

Article in Phytotherapy research : PTR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pharmacological effects ofFrontiers in pharmacology · 2026
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hao QiuDepartment of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China.ORCID https://orcid.org/0009-0006-0509-8950
Chenhui CaiDepartment of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China.
Ying ZhangDepartment of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China.
Sizhen YangDepartment of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China.
Xu HuDepartment of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China.
Tongwei ChuDepartment of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China.

Funding

the Clinical Research Project of the Second Affiliated Hospital of Army Medical University 2018XLC2016the Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission cstc2020jcyj-msxmX0688
6 · The paper itself

Abstract

Osteoporosis, characterized by osteoclastic bone resorption, has been the focus of research. Studies implicate that reactive oxygen species (ROS) accumulate intracellularly during osteoclastogenesis. Salvianolic acid A (SAA), a compound derived from Salvia miltiorrhiza, has been widely used to treat cardiovascular and cerebrovascular disorders, owing to its antioxidant and anti-inflammatory properties. In this study, we investigated the therapeutic effects of SAA on osteoporotic bone loss in vitro and in osteoporotic mice induced by ovariectomy (OVX) and explored the underpinning mechanisms. In vitro, SAA significantly restrained osteoclastogenesis and osteoclastic resorption in a dose- and time-dependent manner. SAA markedly blocked the expression of osteoclast-specific genes and proteins such as NFATc1 and c-Fos. Specifically, SAA reduced ROS production by enhancing the expression and nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) to activate HO-1 and catalase, with no effect on Bach1. In addition, SAA simultaneously suppressed the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathway, ultimately arresting NFATc1 expression to constrain the differentiation and function of osteoclasts. Micro-CT and histological evidence demonstrated that SAA at a nontoxic dose successfully reduced bone loss induced by OVX, with fewer mature osteoclasts. These findings revealed that SAA provides a potential treatment strategy for reducing osteoclast-related bone ailments, including osteoporosis.

Indexed as

Caffeic AcidsLactatesNF-E2-Related Factor 2OsteoporosisReactive Oxygen SpeciesAnimalsBone ResorptionFemaleHeme Oxygenase-1Membrane ProteinsMiceMice, Inbred C57BLNFATC Transcription FactorsNF-kappa BOsteoclastsOsteogenesisCaffeic AcidsHeme Oxygenase-1Hmox1 protein, mouseLactatesMembrane ProteinsNfatc1 protein, mouseNFATC Transcription FactorsNfe2l2 protein, mouseNF-E2-Related Factor 2NF-kappa BReactive Oxygen Speciessalvianolic acid ANFATc1NRF2OsteoclastROSSAA

Identifiers

PMID40765418
PMCPMC12605832

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.